Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin as Second-line Treatment for High-grade Pancreatic Neuroendocrine Tumors
KCT0009931Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Jan 2025
- Countries
- 1
- Sponsor
- Boryung
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Drugs
- lurbinectedin
- Conditions
- islet cell tumor
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in islet cell tumor, sponsored by Boryung. Planned start Jan 2025; status: not yet recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Lurbinectedin monotherapy
Single treatment arm in which all eligible patients receive lurbinectedin as second-line therapy for high-grade pancreatic neuroendocrine tumors.
03
Who it enrols
Adult patients with high-grade malignant pancreatic neuroendocrine tumors who are receiving lurbinectedin as second-line therapy after prior treatment.
Beyond the preview
Go deeper on KCT0009931.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009931.